Diana Wagner, MD
Endocrinology, Diabetes & Metabolism · Vernon, CTNPI 1790893022
Payments from drug & device makers
Across 215 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novo Nordisk$643
- Dexcom, Inc.$328
- Lilly USA, LLC$195
- Medtronic$177
- Xeris Pharmaceuticals, Inc.$165
- plus $896 from 23 others
What the payments were for
- Food & beverage$3,886100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 84 | $1,495 |
| Novo Nordisk | 44 | $643 |
| Dexcom, Inc. | 19 | $328 |
| Lilly USA, LLC | 8 | $195 |
| Medtronic(2 entities) | 7 | $177 |
| Xeris Pharmaceuticals, Inc. | 10 | $165 |
| Insulet Corporation | 7 | $144 |
| AstraZeneca(2 entities) | 5 | $119 |
| Boehringer Ingelheim | 3 | $63 |
| Amphastar Pharmaceuticals, Inc. | 2 | $54 |
| Amgen | 2 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Ultragenyx Pharmaceutical Inc. | 1 | $46 |
| Antares Pharma, Inc. | 2 | $43 |
| IBSA Pharma Inc. | 2 | $34 |
| Ascensia Diabetes Care US Inc. | 2 | $30 |
| Bayer | 1 | $29 |
| Johnson & Johnson | 2 | $27 |
| BETA Bionics, Inc. | 1 | $26 |
| Endo Pharmaceuticals Inc. | 2 | $23 |
| Sequel Med Tech, LLC | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
| Cequr Corporation | 1 | $20 |
| Gilead | 1 | $20 |
| Corcept Therapeutics | 1 | $17 |
| Companion Medical, Inc. | 1 | $16 |
| Nalpropion Pharmaceuticals LLC | 1 | $14 |
| Strongbridge US Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,899 in reported general payments places this provider in the 65th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 181 | $202,046 |
| MounjaroTirzepatide | 171 | $197,555 |
| TrulicityDulaglutide | 128 | $175,235 |
| JanuviaSitagliptin Phosphate | 123 | $126,741 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $123,091 |
| ProliaDenosumab | 65 | $115,356 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $94,361 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 400 | $93,708 |
| Humalog Kwikpen U-200Insulin Lispro | 38 | $75,514 |
| JardianceEmpagliflozin | 37 | $59,088 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $57,018 |
| Humalog Kwikpen U-100Insulin Lispro | 172 | $56,282 |
| FarxigaDapagliflozin Propanediol | 60 | $54,701 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $47,015 |
| Gvoke Hypopen 2-PackGlucagon | 74 | $45,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $195 | $391,954339 claims |
| Novo NordiskOzempic, Novolog | $643 | $227,680235 claims |
| AmgenProlia | $49 | $115,35665 claims |
| Boehringer IngelheimJardiance, Tradjenta | $63 | $72,28050 claims |
| AstraZenecaFarxiga | $119 | $54,70160 claims |
| Johnson & JohnsonInvokana | $27 | $23,12015 claims |
| Sanofi-aventis U.S. LLCLantus | $47 | $6,83722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Vernon
- Yasmine KhanVernon$7K
- Ania JastreboffNew Haven$2.2M
- Ilja HulinskyBridgeport$1.6M
- Gerald ShulmanNew Haven$1M
- Karl InsognaNew Haven$903K
- Clemens BergwitzNew Haven$735K
- Egils BogdanovicsTorrington$608K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.